Catalyst Pharmaceuticals Inc expected to post earnings of 27 cents a share - Earnings Preview

Catalyst Pharmaceuticals

26/02/2024 21:40

* Catalyst Pharmaceuticals Inc  CPRX.OQ   CPRX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
February 28 for the period ending December 31 2023
    * The Coral Gables Florida-based  company is expected to
report a
74.7% increase in revenue to $106.12 million from $60.76 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data. (SAL is on Total revenue basis)
    * ​LSEG's mean analyst estimate for Catalyst Pharmaceuticals
Inc
is for earnings of 27 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Catalyst
Pharmaceuticals Inc is $25.00​, above​ its last closing price
of $14.04. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.38       -0.28      -0.29     Missed  -1.8
 Jun. 30 2023  0.42        0.36       0.53      Beat    48.9
 Mar. 31 2023  0.32        0.32       0.26      Missed  -19.3​
 Dec. 31 2022  0.23        0.21       0.22      Beat    3.8
 ​​Sep.        0.19        0.19       0.20      Beat    5.3
 30 2022                                                
 Jun. 30 2022  0.17        0.17       0.20      Beat    17.6​
 Mar. 31 2022  0.14        0.14       0.12      Missed  -11.8
 Dec. 31 2021  0.12        0.12       0.09      Missed  -22.4
 This summary was machine generated February 26 at 21:40 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)